Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 28 Publications

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnLOJVKSzVyPUCuNFAxODNzNzFOwG0> NIT0dW1USU6JRWK=
SK-MEL-30 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzoNlM5UUN3ME2wMlAxODN3NTFOwG0> NXvkZXNZW0GQR1XS
NALM-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSPG8yUUN3ME2wMlAxODN3NjFOwG0> M3eyeXNCVkeHUh?=
KYSE-450 NH;ERnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP2eZI1UUN3ME2wMlAxODR4OTFOwG0> MmHaV2FPT0WU
BHY M3[zUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jDS2lEPTB;MD6wNFA3ODFizszN MlvuV2FPT0WU
GR-ST NGXYN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMECwOlQ5KM7:TR?= NH70d|NUSU6JRWK=
786-0 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS3TWM2OD1yLkCwNFc4PiEQvF2= NFrycGlUSU6JRWK=
C-33-A NGHENGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fZOGlEPTB;MD6wNFA5PDhizszN NF;MT3VUSU6JRWK=
BHT-101 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTuSJhKSzVyPUCuNFAyODZizszN Moj4V2FPT0WU
EB2 NFHoe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXXTWM2OD1yLkCwNVE5KM7:TR?= NE\OOpdUSU6JRWK=
G-361 NFXDZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLLTWM2OD1yLkCwNVI1KM7:TR?= M1fPeHNCVkeHUh?=
KE-37 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMECxNlgh|ryP NX;wbnVMW0GQR1XS
MHH-PREB-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi2WHdyUUN3ME2wMlAxOTRizszN M{Pk[nNCVkeHUh?=
MCF7 NWPqNmsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rNWmlEPTB;MD6wNFE2QSEQvF2= M1PHeXNCVkeHUh?=
LOUCY NEDGdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPoS45KSzVyPUCuNFAyPzVizszN NE[wOXVUSU6JRWK=
EW-7 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHrfHJkUUN3ME2wMlAxOTd3IN88US=> M2nvNXNCVkeHUh?=
KYSE-510 M3XnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv3TWM2OD1yLkCwNlM{KM7:TR?= M1HLenNCVkeHUh?=
SK-MEL-3 NY\mbodjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\uc2lEPTB;MD6wNFI3PCEQvF2= M1S1bXNCVkeHUh?=
HAL-01 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle2TWM2OD1yLkCwNlk4KM7:TR?= NEnoNJpUSU6JRWK=
HCC2998 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HBNWlEPTB;MD6wNFM{PSEQvF2= M4nkcXNCVkeHUh?=
A375 MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESwSGZKSzVyPUCuNFA{PSEQvF2= NX7WVWNQW0GQR1XS
MZ7-mel MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17uW2lEPTB;MD6wNFM6QSEQvF2= M3LJOHNCVkeHUh?=
SH-4 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj1U5YzUUN3ME2wMlAxPDF5IN88US=> NIHZdHpUSU6JRWK=
HT-144 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLYOm1jUUN3ME2wMlAxPDNizszN M1;hV3NCVkeHUh?=
KYSE-140 M4\rd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhN|VKSzVyPUCuNFA1OzVizszN NX3od5ppW0GQR1XS
PSN1 Mo\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\xPXhKSzVyPUCuNFA1PjdizszN NX\zUlhpW0GQR1XS
COLO-679 NIf2c|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKxXlFGUUN3ME2wMlAxPDl6IN88US=> MYDTRW5ITVJ?
SW620 M3zsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXMfoRYUUN3ME2wMlAxPTFzIN88US=> Mn3SV2FPT0WU
HGC-27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInMNGNKSzVyPUCuNFA2OjRizszN MmjoV2FPT0WU
IGROV-1 NVnlbZhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEC2JO69VQ>? NFfpUWhUSU6JRWK=
IGR-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC2NFEh|ryP MW\TRW5ITVJ?
EW-1 NH7xT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQ[|FqUUN3ME2wMlAxPjVzIN88US=> Ml3YV2FPT0WU
769-P NELlfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMZ2hKSzVyPUCuNFA3PzhizszN MYPTRW5ITVJ?
HN MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfpTWM2OD1yLkCwOlc6KM7:TR?= NUfqN|RkW0GQR1XS
SIG-M5 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC4TWM2OD1yLkCwO|Eh|ryP MVPTRW5ITVJ?
IST-MEL1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rCWGlEPTB;MD6wNFgyQCEQvF2= M4fSOXNCVkeHUh?=
ST486 NEf1TpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlTWM2OD1yLkCwPFI2KM7:TR?= M3jye3NCVkeHUh?=
ES7 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nESmlEPTB;MD6wNFg1PiEQvF2= MWrTRW5ITVJ?
GAK NI\IUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXPc2lMUUN3ME2wMlAxQDR6IN88US=> M1vheHNCVkeHUh?=
BB30-HNC NH;5[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorOTWM2OD1yLkCwPFU5KM7:TR?= MYrTRW5ITVJ?
IPC-298 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;BbZlOUUN3ME2wMlAxQTJ5IN88US=> NYTXXIx5W0GQR1XS
NKM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjzTGJ{UUN3ME2wMlAxQTd{IN88US=> M37UOXNCVkeHUh?=
RKO NGf0[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED5ZXRKSzVyPUCuNFExPDRizszN NYfOZXdKW0GQR1XS
ACN M{H2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnkbpJKSzVyPUCuNFEyOzFizszN M4rs[nNCVkeHUh?=
SW1417 M3nLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrE[FNKSzVyPUCuNFEzOjVizszN M2[5eHNCVkeHUh?=
SR NGfnRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuwOmdKSzVyPUCuNFEzOzVizszN MnjVV2FPT0WU
SNG-M M3vFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\CUmdqUUN3ME2wMlAyOzF5IN88US=> M4rPcnNCVkeHUh?=
CAL-12T MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Ue2lEPTB;MD6wNVM1PiEQvF2= MlTqV2FPT0WU
HSC-3 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEGzOVUh|ryP NYTMWpRHW0GQR1XS
DOHH-2 NH;KTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmroTWM2OD1yLkCxOFEzKM7:TR?= NIHHfnpUSU6JRWK=
NB69 NEO2XHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHwd3U1UUN3ME2wMlAyPTZ3IN88US=> M{jYT3NCVkeHUh?=
LC-2-ad MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OyW2lEPTB;MD6wNVU5OSEQvF2= NInz[|VUSU6JRWK=
RVH-421 NHjiXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjl[5d2UUN3ME2wMlAyPjd2IN88US=> MXXTRW5ITVJ?
TGW MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOzTWM2OD1yLkCxO|M6KM7:TR?= M2[wbXNCVkeHUh?=
HCC1569 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHPTWM2OD1yLkCxO|k4KM7:TR?= NGe4cHRUSU6JRWK=
CAL-85-1 NH3wfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn6N4JOUUN3ME2wMlAyQDN{IN88US=> MWjTRW5ITVJ?
RPMI-8402 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzHTWM2OD1yLkCxPFU5KM7:TR?= MWLTRW5ITVJ?
THP-1 NFXHW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DyZmlEPTB;MD6wNVk6QCEQvF2= NGqzZ2VUSU6JRWK=
ONS-76 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PpeWlEPTB;MD6wNlA{PiEQvF2= MUXTRW5ITVJ?
A2780 M4XPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TVU2lEPTB;MD6wNlA4QSEQvF2= MWDTRW5ITVJ?
RPMI-2650 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEKyPVYh|ryP M1:5NHNCVkeHUh?=
MEL-HO NIDMfmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml32TWM2OD1yLkCyN|Q5KM7:TR?= NHfabHZUSU6JRWK=
MC-CAR M2jPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nUWGlEPTB;MD6wNlM2PiEQvF2= NWT2Rmc1W0GQR1XS
HSC-2 NGrJWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEK0OlYh|ryP MVnTRW5ITVJ?
MEL-JUSO NYPoe4U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf6VVE6UUN3ME2wMlAzPDd|IN88US=> NUH5bVJjW0GQR1XS
CAL-62 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHBSnpRUUN3ME2wMlAzPjB{IN88US=> MYjTRW5ITVJ?
DMS-273 NX\D[YxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnyZoZKSzVyPUCuNFI5PDdizszN M2LMRnNCVkeHUh?=
S-117 M3G2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\lRmlEPTB;MD6wNlkxPiEQvF2= NG\kSWdUSU6JRWK=
SUP-T1 Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnNe4dKSzVyPUCuNFI6PDlizszN NULuZZI4W0GQR1XS
MZ2-MEL M4\qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnWVHg{UUN3ME2wMlAzQTV7IN88US=> MlP5V2FPT0WU
KYSE-270 M4jYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzlTWM2OD1yLkCyPVc3KM7:TR?= Ml3GV2FPT0WU
CMK MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnYTWM2OD1yLkCzNFI{KM7:TR?= MWnTRW5ITVJ?
8505C NX\NclJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\jc2lEPTB;MD6wN|A1KM7:TR?= MV\TRW5ITVJ?
NUGC-3 NXXUTmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEOwOFgh|ryP MVTTRW5ITVJ?
A101D M4DwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVixfoRKUUN3ME2wMlA{ODV3IN88US=> MmniV2FPT0WU
G-401 NIHiNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nWNWlEPTB;MD6wN|A6OyEQvF2= M4Pp[nNCVkeHUh?=
OVCAR-8 NFHxbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEOxNFch|ryP NHjpcVdUSU6JRWK=
IMR-5 NHyxRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jtTGlEPTB;MD6wN|I1PCEQvF2= MoG4V2FPT0WU
DoTc2-4510 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlixTWM2OD1yLkCzN|k{KM7:TR?= NXHTV|VUW0GQR1XS
HOS NEXUS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnI[YREUUN3ME2wMlA{PDd|IN88US=> MVrTRW5ITVJ?
HEC-1 M37WbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jJR2lEPTB;MD6wN|Y5KM7:TR?= MU\TRW5ITVJ?
SW756 M17XcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEO4NlEh|ryP NF[xPYRUSU6JRWK=
NCI-H64 NE\sT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\WTWM2OD1yLkCzPFQzKM7:TR?= NGXCdXpUSU6JRWK=
EW-16 M4T5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECwbmtKSzVyPUCuNFM6ODlizszN NInN[WhUSU6JRWK=
CAL-51 NEGzRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCyNZhwUUN3ME2wMlA1ODB3IN88US=> MU\TRW5ITVJ?
KYSE-150 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37zV2lEPTB;MD6wOFAyOSEQvF2= MUDTRW5ITVJ?
SW1710 M3rObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMESwNVgh|ryP NGDHSVFUSU6JRWK=
HuP-T4 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTPOoVKSzVyPUCuNFQyOThizszN NFr1XllUSU6JRWK=
LB373-MEL-D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7zfGRKSzVyPUCuNFQzOzJizszN NYHReWxUW0GQR1XS
EW-13 M{fMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfTcYVZUUN3ME2wMlA1PDB4IN88US=> Ml7uV2FPT0WU
HT-29 M3\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBdGlEPTB;MD6wOFQ6KM7:TR?= NFPoU5BUSU6JRWK=
SCC-25 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr6WolpUUN3ME2wMlA1PDl2IN88US=> MoXDV2FPT0WU
REH MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMES2N|Uh|ryP M364Z3NCVkeHUh?=
L-363 NULQUnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:3V|NoUUN3ME2wMlA1Pjd7IN88US=> NE\a[oJUSU6JRWK=
NCI-H1770 M2XFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMES2PVch|ryP MWnTRW5ITVJ?
CHL-1 M1jDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTTTWM2OD1yLkC0PFU4KM7:TR?= MXvTRW5ITVJ?
ES1 NWL4fnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMES4PFUh|ryP NFrxW2FUSU6JRWK=
SCC-15 NXfQW|RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e3U2lEPTB;MD6wOFkxOiEQvF2= NUW4RmhVW0GQR1XS
MRK-nu-1 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMES5N|Yh|ryP NEDmcWhUSU6JRWK=
PF-382 M4S0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvFZ|NKSzVyPUCuNFQ6OzlizszN NWHjd|JSW0GQR1XS
COLO-680N NVmzd2J2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y5ZmlEPTB;MD6wOVA1PyEQvF2= NY\aTIpIW0GQR1XS
LK-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nSR2lEPTB;MD6wOVA3OyEQvF2= MnTYV2FPT0WU
NCI-H2342 M3TZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjiZpNKSzVyPUCuNFUyOTdizszN M1XMT3NCVkeHUh?=
HMV-II NVLBWnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnrVI9EUUN3ME2wMlA2OjN7IN88US=> NVnlXGl4W0GQR1XS
PC-14 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm5TWM2OD1yLkC1NlUzKM7:TR?= M2rsPHNCVkeHUh?=
COLO-320-HSR M4n3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljyTWM2OD1yLkC1Nlg6KM7:TR?= MUTTRW5ITVJ?
697 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLRdGRKSzVyPUCuNFU{OjNizszN NULYU4hyW0GQR1XS
NEC8 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEW1PUDPxE1? M2rmN3NCVkeHUh?=
LCLC-97TM1 NFfPeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHpbXZMUUN3ME2wMlA2PTl2IN88US=> MmjsV2FPT0WU
Daoy MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;oc4J6UUN3ME2wMlA2PjF4IN88US=> MkXXV2FPT0WU
ETK-1 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3LTWM2OD1yLkC1OlczKM7:TR?= M2fDWXNCVkeHUh?=
A388 M1[0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz6TWM2OD1yLkC1Olk2KM7:TR?= M3m3XHNCVkeHUh?=
COLO-205 NXvpPJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEW3NVYh|ryP MnPHV2FPT0WU
SK-PN-DW NWm2WJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\PTWM2OD1yLkC1O|I6KM7:TR?= M1;zcnNCVkeHUh?=
SF268 NIP3[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEW3OVYh|ryP MmCxV2FPT0WU
OCI-AML2 NHzLZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XTSmlEPTB;MD6wOVc4PyEQvF2= NGi1XHRUSU6JRWK=
GAMG Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEW4JO69VQ>? M{DFc3NCVkeHUh?=
BCPAP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKXJJKSzVyPUCuNFU5QTJizszN MX7TRW5ITVJ?
BC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD1yLkC2NFIzKM7:TR?= MkK3V2FPT0WU
IA-LM MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PzRWlEPTB;MD6wOlA2OyEQvF2= NIXEXVNUSU6JRWK=
NCI-H1299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHWT4ZHUUN3ME2wMlA3OTNizszN MUXTRW5ITVJ?
COR-L23 NHLHSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHjRoNZUUN3ME2wMlA3OTN2IN88US=> MYDTRW5ITVJ?
KYSE-180 NHTDNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfqTWM2OD1yLkC2NVQzKM7:TR?= NXHpbphQW0GQR1XS
LOXIMVI MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwME[xPFgh|ryP MWLTRW5ITVJ?
BL-41 NU\rU2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPCc49KSzVyPUCuNFYzOTlizszN NFTTSlVUSU6JRWK=
BL-70 NW\SOJltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwME[zNFIh|ryP MoXhV2FPT0WU
NOS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPpcFNKSzVyPUCuNFY1OTFizszN NF2xe2JUSU6JRWK=
NB13 NV;nSphbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OyfGlEPTB;MD6wOlQzOSEQvF2= M2f2bnNCVkeHUh?=
CAL-27 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;aTWM2OD1yLkC2OFY1KM7:TR?= MnjuV2FPT0WU
CA46 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwME[1N|ch|ryP NFT3U3pUSU6JRWK=
SW962 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nMXGlEPTB;MD6wOlU3QSEQvF2= M4fpTHNCVkeHUh?=
NCI-H226 NWn6NoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwME[2N|Ih|ryP MY\TRW5ITVJ?
KYSE-70 NVjmZ4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvpRo1KSzVyPUCuNFY6PDVizszN M{TlZnNCVkeHUh?=
Daudi M2TvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\qTWM2OD1yLkC3NFgyKM7:TR?= MYfTRW5ITVJ?
SW626 M{S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHNVIF3UUN3ME2wMlA4OjB2IN88US=> MXXTRW5ITVJ?
ESS-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEeyOFYh|ryP Mlj2V2FPT0WU
YT MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7QeJZKSzVyPUCuNFc{PDVizszN NITpPFBUSU6JRWK=
P12-ICHIKAWA NVfEcndMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEezOFkh|ryP MoHmV2FPT0WU
BxPC-3 NXLvRnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHBTWM2OD1yLkC3OFU5KM7:TR?= M3;WVXNCVkeHUh?=
CTV-1 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEe1NVch|ryP M3:wWXNCVkeHUh?=
MLMA NELUWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne0TWM2OD1yLkC3OVM1KM7:TR?= NXvU[nZ7W0GQR1XS
WSU-NHL NFSybopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEe1OVQh|ryP NInCdW9USU6JRWK=
CTB-1 NUj5OIVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jTXmlEPTB;MD6wO|U5QCEQvF2= NIrOUFdUSU6JRWK=
MMAC-SF NHixd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\kTWM2OD1yLkC3OlY5KM7:TR?= NWL6U2tJW0GQR1XS
8-MG-BA MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\EUlZKSzVyPUCuNFc5ODFizszN MW\TRW5ITVJ?
NCI-H358 MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlOzTWM2OD1yLkC3PFc6KM7:TR?= MYnTRW5ITVJ?
BFTC-905 M3;UUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTuU|h2UUN3ME2wMlA4QTB7IN88US=> NXjJeJRqW0GQR1XS
NCI-H727 NXHpb204T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvvSFZKSzVyPUCuNFgxPTNizszN NXq0VJJ3W0GQR1XS
CHP-212 NV;NbHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEiwPVUh|ryP MVjTRW5ITVJ?
HOP-62 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PubmlEPTB;MD6wPFI1PSEQvF2= NYLpXoRwW0GQR1XS
CESS NE[xT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEiyOlkh|ryP MUfTRW5ITVJ?
HuCCT1 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPCTWM2OD1yLkC4N|M{KM7:TR?= NGL6XFNUSU6JRWK=
DEL M3[1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEizOFch|ryP NVjmOJVxW0GQR1XS
5637 NHTBVYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\0VolKSzVyPUCuNFg{PjdizszN MVnTRW5ITVJ?
RS4-11 NVv4bYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD1yLkC4OFk4KM7:TR?= NUHacVk2W0GQR1XS
KURAMOCHI MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEi1NFkh|ryP NFHUd4FUSU6JRWK=
A427 NEPPXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEi1NVIh|ryP NEjjRY9USU6JRWK=
A3-KAW M3\1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;PTWM2OD1yLkC4OVY3KM7:TR?= NUWwWY1pW0GQR1XS
LS-123 M13nOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HOdWlEPTB;MD6wPFcyQSEQvF2= NEK3WZhUSU6JRWK=
LoVo M1\JZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnBdXk2UUN3ME2wMlA5PzJizszN NFLS[FhUSU6JRWK=
PA-1 NH;wNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEi3Olkh|ryP NV\RbWNWW0GQR1XS
CP50-MEL-B MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fobWlEPTB;MD6wPFc6OyEQvF2= Mof0V2FPT0WU
A431 NYXlNIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEi4NFEh|ryP NGmxWXpUSU6JRWK=
HCT-116 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHFTWM2OD1yLkC4PFAzKM7:TR?= MX7TRW5ITVJ?
A4-Fuk NHjGPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC3TWM2OD1yLkC4PVQ4KM7:TR?= NHfpW2hUSU6JRWK=
RPMI-6666 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETjcIRKSzVyPUCuNFg6PjdizszN NHP6doZUSU6JRWK=
Calu-6 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEmwNlkh|ryP Mln3V2FPT0WU
KMOE-2 NYTlXGQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH1TWM2OD1yLkC5NFM6KM7:TR?= M{K0TXNCVkeHUh?=
A704 NHTMZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1npTGlEPTB;MD6wPVE2KM7:TR?= NHH3eWhUSU6JRWK=
HO-1-N-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG5TWM2OD1yLkC5NlQ6KM7:TR?= Moq5V2FPT0WU
NCI-H2122 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjPcGZKSzVyPUCuNFk{PzhizszN MWnTRW5ITVJ?
U-698-M MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXLVIpKSzVyPUCuNFk1ODlizszN NVPsbHM6W0GQR1XS
IST-SL2 MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHnbFg5UUN3ME2wMlA6PDZ6IN88US=> M4q5bXNCVkeHUh?=
TE-10 NFv0RodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\qWZVKSzVyPUCuNFk2QDRizszN M37vbHNCVkeHUh?=
PANC-03-27 NFjhO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;iXoNnUUN3ME2wMlA6PjdzIN88US=> MkTVV2FPT0WU
KYSE-410 M3LyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u3V2lEPTB;MD6wPVc6PyEQvF2= MY\TRW5ITVJ?
TE-8 NX3DeWh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LE[GlEPTB;MD6wPVg5PSEQvF2= NWLZXYNpW0GQR1XS
MN-60 NHqz[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2yc4N1UUN3ME2wMlA6QDl5IN88US=> NUDIem9RW0GQR1XS
NCI-H460 NHr3b|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXFTWM2OD1yLkGwNFkh|ryP NELwflFUSU6JRWK=
LB771-HNC MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPhemdHUUN3ME2wMlExOjV3IN88US=> MlXGV2FPT0WU
ES4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjrTWM2OD1yLkGwNlY1KM7:TR?= NGDiZXFUSU6JRWK=
HUTU-80 NGXSNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\WWmlEPTB;MD6xNFM3PSEQvF2= MUTTRW5ITVJ?
647-V M4jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLLXXhKSzVyPUCuNVA1ODhizszN NX7p[Id6W0GQR1XS
HTC-C3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnWTWM2OD1yLkGwOFMzKM7:TR?= MYTTRW5ITVJ?
NTERA-S-cl-D1 NEDTe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUC0OFgh|ryP MYLTRW5ITVJ?
A2058 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO2c3VKSzVyPUCuNVA3PTVizszN NGnES3FUSU6JRWK=
MZ1-PC M4rXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjGOIJKSzVyPUCuNVA5OyEQvF2= NHG3RWNUSU6JRWK=
J82 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTzPXZKSzVyPUCuNVA5QDRizszN M2n6N3NCVkeHUh?=
ARH-77 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMUGg{txO NY\ZdVFzW0GQR1XS
Ca9-22 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGyTWM2OD1yLkGxNVI5KM7:TR?= MYPTRW5ITVJ?
NCI-H1648 M1q1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMUGyPFYh|ryP NIfzflRUSU6JRWK=
MC116 NYq2O2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMUGzN|ch|ryP NUPxZoFSW0GQR1XS
EoL-1-cell NHW2OoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjCSZdnUUN3ME2wMlEyPDZ5IN88US=> NFfWdG9USU6JRWK=
PANC-10-05 NIjHb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPPTWM2OD1yLkGxOFkyKM7:TR?= NXnZdYZZW0GQR1XS
SF539 M2DwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMUG2NVYh|ryP M1LKeXNCVkeHUh?=
ES8 NIHJV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\4PFN{UUN3ME2wMlEyPjN|IN88US=> NEDjT41USU6JRWK=
NCI-H810 NWXWcW9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXIPI9KSzVyPUCuNVE3PjRizszN M1\ycnNCVkeHUh?=
J-RT3-T3-5 M2Szfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jRUGlEPTB;MD6xNVc2KM7:TR?= MXnTRW5ITVJ?
NY NHewTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPm[IdZUUN3ME2wMlEyQDF5IN88US=> MnHGV2FPT0WU
NCI-SNU-1 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LMOWlEPTB;MD6xNlE1QCEQvF2= Mk[2V2FPT0WU
EFM-19 NFXwUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL1S|ZKSzVyPUCuNVI{PzRizszN MULTRW5ITVJ?
HCC1806 M4HVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELNbHpKSzVyPUCuNVI{QDNizszN MU\TRW5ITVJ?
HCE-T MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUK1N|Eh|ryP NX3xT4VGW0GQR1XS
HT-1376 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:yeJl6UUN3ME2wMlEzPjZ6IN88US=> Mmr0V2FPT0WU
BE-13 NInxOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PW[GlEPTB;MD6xNlg3PiEQvF2= M1\VbHNCVkeHUh?=
NCI-H520 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm2THBKSzVyPUCuNVI5PjdizszN MV\TRW5ITVJ?
SK-MES-1 NVLCPVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUK5NVMh|ryP NVTUU2xQW0GQR1XS
SNU-423 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMUK5NVQh|ryP Ml2zV2FPT0WU
Ramos-2G6-4C10 NHy3NZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUK5NVYh|ryP MW\TRW5ITVJ?
EW-18 NEDnZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDkTWM2OD1yLkGzNFI3KM7:TR?= NUfCNHpFW0GQR1XS
NCI-H2087 M33tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrkcpRKSzVyPUCuNVMxOjdizszN MUnTRW5ITVJ?
COLO-792 NWT2[IFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;iSWlEPTB;MD6xN|E3PSEQvF2= NXO3e4h7W0GQR1XS
QIMR-WIL MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnYTWM2OD1yLkGzNlI{KM7:TR?= M4HXe3NCVkeHUh?=
ACHN M1\3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTlTWM2OD1yLkGzNlQ4KM7:TR?= Mn7TV2FPT0WU
RPMI-8866 M2DJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMUOyOlEh|ryP MorvV2FPT0WU
SK-LU-1 NHXnPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i0PWlEPTB;MD6xN|Q1QSEQvF2= NH7ZdolUSU6JRWK=
SK-UT-1 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG0bYhXUUN3ME2wMlE{PjJ6IN88US=> Mlv1V2FPT0WU
MFE-296 NW\lNlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL0dJRrUUN3ME2wMlE{QDZ2IN88US=> M1fOcXNCVkeHUh?=
RD MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfLVJZKSzVyPUCuNVM6QTdizszN MmDvV2FPT0WU
LS-411N M{\xW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftTWM2OD1yLkG0Nlk2KM7:TR?= NUXlWJltW0GQR1XS
NCI-H747 NH64eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGKwNGtKSzVyPUCuNVQ{KM7:TR?= NV3jfZpnW0GQR1XS
ES6 NXXvOWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUSzOkDPxE1? MVLTRW5ITVJ?
TE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4[GlEPTB;MD6xOFQxPyEQvF2= M2\WcHNCVkeHUh?=
SJSA-1 NUHhfJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3kSotKSzVyPUCuNVQ4ODdizszN M{P1UHNCVkeHUh?=
NCI-H1355 M{DTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUWyPVMh|ryP NUK4cY0{W0GQR1XS
HEL NYP2[ng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjGS45JUUN3ME2wMlE2PDR5IN88US=> M3vuOXNCVkeHUh?=
639-V M4DDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjrb|NKSzVyPUCuNVU2QTZizszN M1rFPXNCVkeHUh?=
AN3-CA M1\GPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjxdIxQUUN3ME2wMlE2PjN7IN88US=> NWC0Tpk1W0GQR1XS
SK-MEL-2 NWHJRZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofCTWM2OD1yLkG1OlY5KM7:TR?= NHHwbVFUSU6JRWK=
SW872 NGDlR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PoUGlEPTB;MD6xOlA1OiEQvF2= M{XGUXNCVkeHUh?=
DU-4475 M3jwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMU[xOlIh|ryP NHj3d2FUSU6JRWK=
YKG-1 NUDkNYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnPTWM2OD1yLkG2Nlc{KM7:TR?= NV\CN41lW0GQR1XS
GT3TKB NWrDUXplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXy0V5l5UUN3ME2wMlE3Ojh|IN88US=> M1;5XHNCVkeHUh?=
GB-1 M4rQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMU[0NlQh|ryP Mn71V2FPT0WU
KARPAS-422 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMU[1O|Qh|ryP NIjWbZVUSU6JRWK=
ATN-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfGW4lKSzVyPUCuNVY3PTZizszN MmXWV2FPT0WU
HLE MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHLTWM2OD1yLkG2PFc4KM7:TR?= MmfqV2FPT0WU
D-542MG NFfEUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjUTWM2OD1yLkG2PVg3KM7:TR?= NFOzXZJUSU6JRWK=
EB-3 NW\FV5RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;SW5VKSzVyPUCuNVc{OSEQvF2= MmT3V2FPT0WU
HCC1143 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXCNFBKSzVyPUCuNVc{QTZizszN Ml;lV2FPT0WU
DJM-1 NYfaWZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvWV|dKSzVyPUCuNVc1PTFizszN MWrTRW5ITVJ?
BT-474 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PUZWlEPTB;MD6xO|Q5QSEQvF2= NHftdplUSU6JRWK=
BB65-RCC NVPzdXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m3PGlEPTB;MD6xO|U1PSEQvF2= NVn4fJJuW0GQR1XS
NCI-H292 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG1dZM5UUN3ME2wMlE4PjBzIN88US=> M3;BZXNCVkeHUh?=
MKN28 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUe2OVMh|ryP NUX0VWtKW0GQR1XS
TK10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;4b2lEPTB;MD6xO|cxOiEQvF2= MUHTRW5ITVJ?
TYK-nu MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfxTWM2OD1yLkG3PVQ6KM7:TR?= M3juR3NCVkeHUh?=
8305C MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7STWM2OD1yLkG3PVcyKM7:TR?= MV\TRW5ITVJ?
MV-4-11 NUi4Z2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f2UmlEPTB;MD6xO|k4PyEQvF2= NInNR5dUSU6JRWK=
NCI-H522 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M161[GlEPTB;MD6xPFA6PCEQvF2= NFPEfIpUSU6JRWK=
Hs-578-T NYLWcW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMUiyPVIh|ryP MXPTRW5ITVJ?
LCLC-103H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfyfnFEUUN3ME2wMlE5PTJ5IN88US=> NInrepZUSU6JRWK=
MHH-ES-1 M37mVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG3[ZBOUUN3ME2wMlE5PjJ7IN88US=> MoDsV2FPT0WU
NCI-H441 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqzcWM2UUN3ME2wMlE6OTR6IN88US=> M3z5cXNCVkeHUh?=
AM-38 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMUmyNlUh|ryP MnX6V2FPT0WU
SW1783 NGi4N5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMUmzNFUh|ryP NF\ITFVUSU6JRWK=
SK-HEP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHYTWM2OD1yLkG5OlM4KM7:TR?= MUnTRW5ITVJ?
OAW-28 NVrEenVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILSVmJKSzVyPUCuNlAyPzhizszN MVTTRW5ITVJ?
TE-15 M4fOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S1[GlEPTB;MD6yNFI2OiEQvF2= NYjmUIVbW0GQR1XS
HCE-4 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvGcolKSzVyPUCuNlAzQDRizszN NYm2VHIzW0GQR1XS
JiyoyeP-2003 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XkR2lEPTB;MD6yNFM{PiEQvF2= MXjTRW5ITVJ?
OVCAR-4 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GwcGlEPTB;MD6yNFYzQCEQvF2= Ml3QV2FPT0WU
SNU-449 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPpUlR4UUN3ME2wMlIxPzl5IN88US=> MXXTRW5ITVJ?
SBC-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPnTWM2OD1yLkKxNlE2KM7:TR?= Mk\ZV2FPT0WU
T84 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfMNXZKSzVyPUCuNlEzPDhizszN MVjTRW5ITVJ?
LP-1 M{foNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGxTWM2OD1yLkKxN|AzKM7:TR?= MmrTV2FPT0WU
MG-63 M4r2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLMTWM2OD1yLkKxN|gzKM7:TR?= MmO3V2FPT0WU
OAW-42 NEfSfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;vZmlEPTB;MD6yNVQ4QCEQvF2= MVXTRW5ITVJ?
L-540 NELCZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMkG1PVgh|ryP NXT5d2lbW0GQR1XS
RH-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPq[YJKSzVyPUCuNlIzPDJizszN M1LnNHNCVkeHUh?=
HCT-15 NV\U[21vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSwTWM2OD1yLkKyOFg1KM7:TR?= NYm2XnY4W0GQR1XS
OCUB-M MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu2TWM2OD1yLkKyOFg5KM7:TR?= M2XpWHNCVkeHUh?=
GP5d Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[5TWM2OD1yLkKyOVI5KM7:TR?= M3XPb3NCVkeHUh?=
NCI-H2030 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHjTWM2OD1yLkKyO|M1KM7:TR?= Mlz0V2FPT0WU
ML-2 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXtTWM2OD1yLkKyPFg6KM7:TR?= NXvzSmdSW0GQR1XS
CAL-39 NIPOelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fBfWlEPTB;MD6yNlk{PiEQvF2= MVnTRW5ITVJ?
MIA-PaCa-2 M2LwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PMcGlEPTB;MD6yN|I5PyEQvF2= MoHiV2FPT0WU
TE-9 M2DqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTBN2hzUUN3ME2wMlI{OzJizszN MonXV2FPT0WU
LB2518-MEL M{PXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFntc|JKSzVyPUCuNlM{PzJizszN M3zuNXNCVkeHUh?=
DB M4r2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3iO5VLUUN3ME2wMlI{PDN6IN88US=> MlrpV2FPT0WU
NCI-H596 NHLjOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPvUVlKSzVyPUCuNlM2PzFizszN MXjTRW5ITVJ?
SW1990 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMkO5OFYh|ryP NXLifpl4W0GQR1XS
P30-OHK M37LTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QSmg6UUN3ME2wMlI1ODVizszN MUPTRW5ITVJ?
ALL-PO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnpTWM2OD1yLkK0NVY6KM7:TR?= M4DQOnNCVkeHUh?=
Saos-2 NYrt[Yk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wcIFKSzVyPUCuNlQ2PzFizszN MoTDV2FPT0WU
MFH-ino NGWzPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjhfYZKSzVyPUCuNlQ3QTJizszN NWC0RmZtW0GQR1XS
OE33 NGjtVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjaSZNLUUN3ME2wMlI2OTFizszN M3PnS3NCVkeHUh?=
Calu-3 MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLT2lEPTB;MD6yOVI6PyEQvF2= M1LDZ3NCVkeHUh?=
HT M3n6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDVRZJKSzVyPUCuNlU3OjFizszN NH7PSIxUSU6JRWK=
LXF-289 NW\pXmxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMkW5PFQh|ryP M3TW[HNCVkeHUh?=
KGN MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnoWmFKSzVyPUCuNlYxQDlizszN MVTTRW5ITVJ?
NCI-H1417 M2TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLUUY1KSzVyPUCuNlY2OjRizszN MYHTRW5ITVJ?
SF126 NIL6TZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj0T|ROUUN3ME2wMlI4OzB{IN88US=> MYTTRW5ITVJ?
SAS NHrld4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMkezNFgh|ryP MoOzV2FPT0WU
22RV1 NVLYTFdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2R2lEPTB;MD6yO|M4QCEQvF2= NITlXoJUSU6JRWK=
GI-1 NWfHRnVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHURY1iUUN3ME2wMlI4PDh5IN88US=> M{HrOnNCVkeHUh?=
ES3 M1j6cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHsd21KSzVyPUCuNlc4PjNizszN NX3FVodJW0GQR1XS
NB1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5VI5GUUN3ME2wMlI4QDd4IN88US=> MULTRW5ITVJ?
NCI-H650 NXm4U29HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITqNGhKSzVyPUCuNlg{ODJizszN M2DOb3NCVkeHUh?=
IST-MES1 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMki1OVQh|ryP M4PMdHNCVkeHUh?=
UM-UC-3 NIn4T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLwTWM2OD1yLkK5NVQh|ryP MWnTRW5ITVJ?
CAL-120 M1zWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMkm2N|Eh|ryP NUTxfYlwW0GQR1XS
UACC-62 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfPfZRKSzVyPUCuN|AzPDFizszN NXzFRodSW0GQR1XS
TE-11 M2qySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHoTWM2OD1yLkOwNlQ6KM7:TR?= MnjnV2FPT0WU
MKN1 M13IXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwM{CzOkDPxE1? NGTjW3BUSU6JRWK=
KS-1 NX76dpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrpXXM2UUN3ME2wMlMxPTJ4IN88US=> MlfiV2FPT0WU
GCIY MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPBXW86UUN3ME2wMlMyODB{IN88US=> M4DLb3NCVkeHUh?=
OVCAR-5 NVjzPG53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzYbmlKSzVyPUCuN|EyODZizszN M4fHbHNCVkeHUh?=
U-266 M4DG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwM{GxOFch|ryP NFrVSZFUSU6JRWK=
Calu-1 NVHMZm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Tte2lEPTB;MD6zNVI5QSEQvF2= NFPTO|lUSU6JRWK=
SK-LMS-1 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwM{G0Nlkh|ryP NXzzc5M{W0GQR1XS
COLO-741 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDsTWM2OD1yLkOxOlE1KM7:TR?= MXXTRW5ITVJ?
RPMI-8226 M362N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwM{G2OFEh|ryP NEOy[pZUSU6JRWK=
KM12 NET4e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjoXpVKSzVyPUCuN|E5OyEQvF2= M{LiPXNCVkeHUh?=
NMC-G1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV74dY83UUN3ME2wMlMyQDZizszN M4HoO3NCVkeHUh?=
SJRH30 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwM{KwOVIh|ryP MlmwV2FPT0WU
COR-L105 NGLvZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OyVGlEPTB;MD6zNlIyQCEQvF2= MWDTRW5ITVJ?
IM-9 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW0TWM2OD1yLkOzNFIyKM7:TR?= NY\sUFd{W0GQR1XS
TE-12 NVqwWFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwM{OzNVch|ryP MoS3V2FPT0WU
KG-1 NHO4dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwM{O0N|Ih|ryP MmX1V2FPT0WU
U251 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T4ZWlEPTB;MD6zN|Q2PiEQvF2= MmLOV2FPT0WU
EFO-27 NYr6b5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v6WGlEPTB;MD6zN|k2OSEQvF2= NYTiXo5JW0GQR1XS
EW-24 NFz3WWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwM{O5PFQh|ryP M{nlZnNCVkeHUh?=
SF295 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV61cZRGUUN3ME2wMlM{QTl7IN88US=> Mlz4V2FPT0WU
MC-IXC NIrDVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwM{S1JO69VQ>? MVjTRW5ITVJ?
NCI-H2405 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vVTWlEPTB;MD6zOFc{OiEQvF2= Mn\DV2FPT0WU
NCI-H2009 NUfOPG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXlTWM2OD1yLkO0O|M6KM7:TR?= NE\vcnpUSU6JRWK=
LB1047-RCC M2q2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfOTWM2OD1yLkO1PFE2KM7:TR?= M1ntNnNCVkeHUh?=
KNS-81-FD M3PGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7qbHFKSzVyPUCuN|Y3PjdizszN MnTVV2FPT0WU
HOP-92 M1zaemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXtRmRNUUN3ME2wMlM3QDNizszN MV7TRW5ITVJ?
L-428 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj6[|NKSzVyPUCuN|cxOTZizszN Ml\vV2FPT0WU
C3A M37ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi0TWM2OD1yLkO3N|c6KM7:TR?= MVHTRW5ITVJ?
NCI-H1792 NFz0dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfYTWM2OD1yLkO3OlU2KM7:TR?= NFjIeWtUSU6JRWK=
HuH-7 NGq0bolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfS[HpKSzVyPUCuN|c6OSEQvF2= NGjJUGtUSU6JRWK=
AGS NFS4PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm5U4FjUUN3ME2wMlM5PjN6IN88US=> MmnuV2FPT0WU
HT-1197 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrzclZKSzVyPUCuN|k1PiEQvF2= NWHFN|BxW0GQR1XS
CGTH-W-1 M3;XS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ubmNrUUN3ME2wMlM6QTF|IN88US=> MorLV2FPT0WU
KNS-42 MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLCTWM2OD1yLkSwNFQ2KM7:TR?= M1HIdHNCVkeHUh?=
HuO-3N1 NWXEToVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M163OGlEPTB;MD60NFA2PSEQvF2= Ml;QV2FPT0WU
VMRC-RCZ NX;ueYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLNe3kzUUN3ME2wMlQxOzB|IN88US=> MV\TRW5ITVJ?
SW954 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\PNVVKSzVyPUCuOFA{OzVizszN MUTTRW5ITVJ?
MES-SA MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNEC1NFUh|ryP NXPtUYo4W0GQR1XS
Ca-Ski NISwfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXte|ZKSzVyPUCuOFA2OjRizszN MU\TRW5ITVJ?
SW13 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCTWM2OD1yLkSwOlI3KM7:TR?= M3L3SnNCVkeHUh?=
NCI-H1437 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK5SYtJUUN3ME2wMlQxQDB3IN88US=> MkTwV2FPT0WU
U-118-MG NHjjfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPnTFVKSzVyPUCuOFA6ODRizszN NVeyd|BbW0GQR1XS
NCI-H1734 NEPxVIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNEKwNVMh|ryP NX\CUZBRW0GQR1XS
HDLM-2 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXyTWM2OD1yLkSyNFM{KM7:TR?= Mn\yV2FPT0WU
AU565 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DXb2lEPTB;MD60NlQ3QCEQvF2= MWfTRW5ITVJ?
FADU M2jaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\1TGRKSzVyPUCuOFI3PDlizszN NIXUSWxUSU6JRWK=
OS-RC-2 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjDOmFDUUN3ME2wMlQ{ODh|IN88US=> NIfneGhUSU6JRWK=
CAMA-1 NXixeIJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH0NXlLUUN3ME2wMlQ{PjJ4IN88US=> NFvoe4tUSU6JRWK=
MONO-MAC-6 MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n5N2lEPTB;MD60N|g1QSEQvF2= MYDTRW5ITVJ?
LB831-BLC M4LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELodoxKSzVyPUCuOFQ{PzFizszN MkfrV2FPT0WU
SW982 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwNES1Nlgh|ryP MYHTRW5ITVJ?
SCC-3 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JO5Z3UUN3ME2wMlQ1PTd7IN88US=> NX30PWNmW0GQR1XS
C32 NYf2PZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwNEWyNlkh|ryP M{nTcXNCVkeHUh?=
BFTC-909 NXS3fW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD1yLkS1Nlk6KM7:TR?= MWrTRW5ITVJ?
MEG-01 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNEWzO|Mh|ryP M{[xUnNCVkeHUh?=
M14 NXH5U5FvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnnZXRKSzVyPUCuOFU6PzlizszN MorpV2FPT0WU
MPP-89 M4DGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fYe2lEPTB;MD60OlI2PiEQvF2= MXjTRW5ITVJ?
HCC1937 M{HPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTqfnhKSzVyPUCuOFY{QDRizszN NVmydXNqW0GQR1XS
SW837 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vEPGlEPTB;MD60OlczOiEQvF2= NGDveWRUSU6JRWK=
DU-145 NEXJWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHGXYpKSzVyPUCuOFY4OjlizszN NUnvSlBFW0GQR1XS
LB996-RCC NXu0UG1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHNTWM2OD1yLkS3NFU1KM7:TR?= NFfL[IJUSU6JRWK=
C8166 NUjye3BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnFSFhCUUN3ME2wMlQ4PCEQvF2= M{Owb3NCVkeHUh?=
MOLT-4 NGfUcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDrTWM2OD1yLkS3O|M1KM7:TR?= MVvTRW5ITVJ?
DMS-53 NXnzVI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DYXGlEPTB;MD60O|gxQSEQvF2= MWjTRW5ITVJ?
TE-5 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\wSGlEPTB;MD60PFMxPSEQvF2= MmjqV2FPT0WU
KYSE-520 NV73Z3JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzI[3lKSzVyPUCuOFg{PDNizszN NYPMRnRrW0GQR1XS
Detroit562 NW\uc3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNEi4OkDPxE1? MoPoV2FPT0WU
SIMA MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX3PW1KSzVyPUCuOFk1OTdizszN NV:0b4lUW0GQR1XS
NCI-H1651 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zZc2lEPTB;MD60PVY4KM7:TR?= NVfme|BtW0GQR1XS
HCC1599 NW\DTJg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1yLkS5PVU2KM7:TR?= NVvVboVzW0GQR1XS
ABC-1 NVvLPINlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfqTWM2OD1yLkWwOFk3KM7:TR?= MmD5V2FPT0WU
CAL-33 NVmwbY5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW1TWM2OD1yLkWwPFQ1KM7:TR?= M1jSW3NCVkeHUh?=
OPM-2 NFTo[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[1cGlEPTB;MD61NFk{PyEQvF2= MVfTRW5ITVJ?
RPMI-7951 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;SZVBKSzVyPUCuOVA6PTdizszN Mne3V2FPT0WU
HT-1080 NHT2NXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5UWlEPTB;MD61NVEyQSEQvF2= NVTNWmN3W0GQR1XS
LC4-1 M{f6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofqTWM2OD1yLkWxOFA{KM7:TR?= Ml;MV2FPT0WU
OVCAR-3 MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\oTWM2OD1yLkWxOVch|ryP MkexV2FPT0WU
CAPAN-1 MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwNUKyPFgh|ryP MXjTRW5ITVJ?
SK-OV-3 M3Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;pTWM2OD1yLkWyOFM1KM7:TR?= NXu2bYN{W0GQR1XS
HuP-T3 NV;n[ZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfMOoRyUUN3ME2wMlUzQDJ5IN88US=> MXzTRW5ITVJ?
NCI-H838 M3jNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:3VmlEPTB;MD61Nlg1QSEQvF2= NUXJUGJ1W0GQR1XS
K5 MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrCNXdvUUN3ME2wMlU{OjBzIN88US=> NVXoVpBLW0GQR1XS
CAL-72 MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXSRWkyUUN3ME2wMlU{Ozh5IN88US=> NUDJc5Z{W0GQR1XS
NH-12 NHfYOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v1WGlEPTB;MD61N|k2QSEQvF2= M4HSTHNCVkeHUh?=
SNB75 MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16xO2lEPTB;MD61OVc{KM7:TR?= MVnTRW5ITVJ?
BPH-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PMeWlEPTB;MD61OlM1PCEQvF2= M4G3OHNCVkeHUh?=
NOMO-1 NYHSTJpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwNU[zO|Ih|ryP NEj4dVRUSU6JRWK=
G-402 NULo[IxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17mSWlEPTB;MD61OlQ6QSEQvF2= Mnq1V2FPT0WU
NCI-H2052 NEPkXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n0eGlEPTB;MD61Olc1OSEQvF2= M{\0eXNCVkeHUh?=
RCM-1 M3:5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITyVohKSzVyPUCuOVcyPjZizszN MVLTRW5ITVJ?
COR-L279 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfsTWM2OD1yLkW3NVg2KM7:TR?= M3PESHNCVkeHUh?=
A253 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNUe1NlUh|ryP MkfCV2FPT0WU
SK-MM-2 NIrxN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ZTWM2OD1yLkW3Olc6KM7:TR?= NYTzcWN3W0GQR1XS
NCI-H1703 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DQWGlEPTB;MD61PVQzPyEQvF2= MmLkV2FPT0WU
UACC-257 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\rTWM2OD1yLkW5OFg4KM7:TR?= NWrWfHB5W0GQR1XS
KALS-1 NFzsUHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvZTWM2OD1yLk[wNFEyKM7:TR?= MX;TRW5ITVJ?
ES5 M4fyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7BUGltUUN3ME2wMlYxPDhizszN MoCwV2FPT0WU
MHH-CALL-2 M37pU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwNkC4PFgh|ryP MYHTRW5ITVJ?
ChaGo-K-1 NUT6VW86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vwUGlEPTB;MD62NVIzQSEQvF2= MlrSV2FPT0WU
TGBC1TKB M4nhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDoTWM2OD1yLk[xPVgh|ryP M4H6V3NCVkeHUh?=
KU-19-19 NE\wcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PdmZKSzVyPUCuOlQ2QDZizszN M3LpenNCVkeHUh?=
COLO-684 NVrtTW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOxb|I2UUN3ME2wMlY2PjFzIN88US=> NF6wS3NUSU6JRWK=
LS-1034 NF7GfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNkW4NVkh|ryP Mn;4V2FPT0WU
RT-112 NHnFe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzmTWM2OD1yLk[2OVg4KM7:TR?= NGnUXWJUSU6JRWK=
Capan-2 M{PNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrDcpc6UUN3ME2wMlY3PjJ{IN88US=> M3PRVHNCVkeHUh?=
HSC-4 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXWOVB{UUN3ME2wMlY3Pjl6IN88US=> NHfUVJdUSU6JRWK=
COLO-824 NYPpcmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWwTWM2OD1yLk[3PFI{KM7:TR?= NEPhfJNUSU6JRWK=
NCI-H2170 NG[4R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\FbVU6UUN3ME2wMlY5OjV6IN88US=> NWC2O2xEW0GQR1XS
GDM-1 M2q0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfNW3dKSzVyPUCuOlg1QTRizszN MVHTRW5ITVJ?
KP-4 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnVPVhKSzVyPUCuOlk2PzNizszN MWnTRW5ITVJ?
VA-ES-BJ NXy4fZNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHsNFZKSzVyPUCuOlk6QDZizszN NFu1c3VUSU6JRWK=
KM-H2 NH\kVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnqO5lsUUN3ME2wMlcxODlzIN88US=> NFvhRVZUSU6JRWK=
HH M3X2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPp[G5KSzVyPUCuO|A3PjJizszN NXTtfXA3W0GQR1XS
DK-MG NUiwNVRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHsdJJKUUN3ME2wMlcyODF4IN88US=> NYHo[GxNW0GQR1XS
VM-CUB-1 NFnSUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1yLkexNlU6KM7:TR?= NUfadYNsW0GQR1XS
COLO-829 M2ricmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXIeGlEUUN3ME2wMlcyQTh3IN88US=> MkX3V2FPT0WU
OMC-1 NYnSN4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;MdZJVUUN3ME2wMlczOTB2IN88US=> NWDmeXV7W0GQR1XS
NB12 M2nEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrL[FNKSzVyPUCuO|I2ODRizszN MkHQV2FPT0WU
NCI-H28 NEC2[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrSTWM2OD1yLke0NFg{KM7:TR?= MlvGV2FPT0WU
A673 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HYRmlEPTB;MD63OVE4PyEQvF2= M3XJeXNCVkeHUh?=
LB2241-RCC NIDSR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M322VWlEPTB;MD63OlA5PyEQvF2= NWDhU3dnW0GQR1XS
CCRF-CEM M3vOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiwTWM2OD1yLke3NFUzKM7:TR?= M136XnNCVkeHUh?=
NCI-H510A MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPQTWM2OD1yLke3NVg3KM7:TR?= NV7DVWtKW0GQR1XS
SW48 M2T3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV31VXJxUUN3ME2wMlc4OzN|IN88US=> NHG2e|NUSU6JRWK=
NCI-H2081 NVLne2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF36TGxKSzVyPUCuO|gyPDdizszN M4PvT3NCVkeHUh?=
RMG-I M1\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwN{iyNVIh|ryP NWHhSmk4W0GQR1XS
LU-99A NIPlbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHBTWM2OD1yLke4OFE{KM7:TR?= NHvSOI1USU6JRWK=
KP-N-YS NFXT[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HsPWlEPTB;MD63PFkzOSEQvF2= NHL5V2RUSU6JRWK=
MDA-MB-231 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rrbWlEPTB;MD64NFE{OSEQvF2= MWjTRW5ITVJ?
U031 M{TCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vQfGlEPTB;MD64NVQzOyEQvF2= NX;ZW2MxW0GQR1XS
EVSA-T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XPUmlEPTB;MD64NVY4OiEQvF2= M332OXNCVkeHUh?=
MDA-MB-157 NGPVOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjXcpZKSzVyPUCuPFIzPzFizszN M{TuN3NCVkeHUh?=
EHEB NX;ubXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P3RmlEPTB;MD64NlI4PiEQvF2= NHzLS3VUSU6JRWK=
KINGS-1 NF3BNmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\mTWM2OD1yLkiyOVU2KM7:TR?= MmO5V2FPT0WU
23132-87 M2W2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;1fVlKSzVyPUCuPFI5PDNizszN MkXPV2FPT0WU
EFO-21 NUPGZnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDpUm1KSzVyPUCuPFQxQDlizszN NIHSWmNUSU6JRWK=
DOK MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKVWlEPTB;MD64OFgh|ryP M1e0NHNCVkeHUh?=
NCI-H2171 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rwTmlEPTB;MD64OFk3KM7:TR?= MnjOV2FPT0WU
NCI-SNU-5 NIHMO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XSfGlEPTB;MD64OVU4KM7:TR?= NFjqWFNUSU6JRWK=
SK-N-DZ MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwOEW5OFMh|ryP M1L5R3NCVkeHUh?=
SNU-C2B M2[zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwOE[4NFEh|ryP MVPTRW5ITVJ?
CP66-MEL M{Ww[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwOEexNUDPxE1? MYjTRW5ITVJ?
SN12C Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInE[IxKSzVyPUCuPFg3OzdizszN NEnwW5RUSU6JRWK=
A172 M3nQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOEi2PVgh|ryP MkXzV2FPT0WU
NCI-H2347 NYDUb25HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwOEi3OVMh|ryP M13KXHNCVkeHUh?=
NCI-H2228 NEC3[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2zb2ZKSzVyPUCuPFk{OzlizszN MWTTRW5ITVJ?
SNU-387 NI\kPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrvUVhXUUN3ME2wMlkxOjZ2IN88US=> NEfR[G1USU6JRWK=
SK-MEL-24 M1HqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3MbZNOUUN3ME2wMlkyOzR2IN88US=> NVnE[YhYW0GQR1XS
MDA-MB-468 M33iR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjD[mlKSzVyPUCuPVE4OyEQvF2= M1jnPXNCVkeHUh?=
NCI-H1694 M1fXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLteHZKSzVyPUCuPVE5PzZizszN M1ywS3NCVkeHUh?=
CCF-STTG1 NVPvSFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHD[GtjUUN3ME2wMlkzPjN5IN88US=> MkezV2FPT0WU
K052 NXnsVIhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LkS2lEPTB;MD65OFA1PyEQvF2= NHP0XHNUSU6JRWK=
NCI-H446 NFTZUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HJVmlEPTB;MD65OVAyKM7:TR?= NX73b5llW0GQR1XS
MFE-280 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\ub|NKSzVyPUCuPVYzQTFizszN NXv5S|VRW0GQR1XS
KU812 M1fwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;4V2VKSzVyPUCuPVk{QDlizszN NWf5WYtIW0GQR1XS
MDA-MB-361 M3riUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrlcHdKSzVyPUCuPVk4PzdizszN NInMWoZUSU6JRWK=
Raji M3fhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HyZmlEPTB;MT6wNlI3PyEQvF2= MX7TRW5ITVJ?
TE-6 MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PCPGlEPTB;MT6wN|U3PiEQvF2= M17TW3NCVkeHUh?=
CAL-148 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K2ZmlEPTB;MT6wOFQ1OyEQvF2= M4e0d3NCVkeHUh?=
NCI-H1963 NXLLTpFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ydmlEPTB;MT6wOFU2OyEQvF2= M4LRN3NCVkeHUh?=
SK-N-AS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP3TWM2OD1zLkC0Olg2KM7:TR?= M1OzWHNCVkeHUh?=
RERF-LC-MS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jLeGlEPTB;MT6wOlM1QSEQvF2= MnTFV2FPT0WU
BEN MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH6ToRrUUN3ME2xMlA4OTN5IN88US=> NVTXfW9oW0GQR1XS
CAS-1 Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwMEmxNlMh|ryP MYnTRW5ITVJ?
SW780 NY\aNI9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrWdlNKSzVyPUGuNFkyQDFizszN NXnDZnd5W0GQR1XS
LU-65 NH3ZdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK3WXJNUUN3ME2xMlA6PDFizszN MoTTV2FPT0WU
D-283MED M4exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XUNWlEPTB;MT6xNlI4OiEQvF2= MYnTRW5ITVJ?
HCC2157 NFK0V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwMUO2OFIh|ryP NVfBOFVXW0GQR1XS
RCC10RGB Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hk[2lEPTB;MT6xOFAxPiEQvF2= NX7lbnFsW0GQR1XS
PLC-PRF-5 NFvqSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\zNHMzUUN3ME2xMlE2OjJ7IN88US=> MVLTRW5ITVJ?
H4 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nxR2lEPTB;MT6xOVQ{QSEQvF2= NE\uXppUSU6JRWK=
TUR NF76VohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3kcIVDUUN3ME2xMlE2PzV{IN88US=> NV;TenVvW0GQR1XS
NCI-H2141 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfWVplKSzVyPUGuNVg6PDZizszN NHz0NVNUSU6JRWK=
PFSK-1 NGTrWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljjTWM2OD1zLkKwOVMzKM7:TR?= M163ZXNCVkeHUh?=
SK-MEL-28 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMkOyNlEh|ryP M1XIRnNCVkeHUh?=
SCC-9 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rLXWlEPTB;MT6yN|Y3PSEQvF2= M2HLXXNCVkeHUh?=
T47D NHqyXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjWPYdLUUN3ME2xMlI{Pjl4IN88US=> Mmn6V2FPT0WU
TCCSUP M1jKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1zLkK1NFI6KM7:TR?= MXLTRW5ITVJ?
SU-DHL-1 NYTMWINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Eem5PUUN3ME2xMlI2OTF6IN88US=> NF;ud2pUSU6JRWK=
HL-60 M4Tj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTFwMkW1PFgh|ryP MkTaV2FPT0WU
NCI-H1436 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni2TWM2OD1zLkK2NVQ6KM7:TR?= NHu1bolUSU6JRWK=
DMS-114 NVfmRocyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMk[2N|Ih|ryP MWnTRW5ITVJ?
BOKU NXXqc4lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\TZYZKSzVyPUGuNlgxQTVizszN MV3TRW5ITVJ?
MS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwMkmwOlkh|ryP M4LG[XNCVkeHUh?=
NCI-H661 NV25UGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH1TWM2OD1zLkOwOFc5KM7:TR?= NFrBVnlUSU6JRWK=
HT-3 NWH0UnNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG0XYNKSzVyPUGuN|A2OjlizszN NV21cpc3W0GQR1XS
CAL-54 M4\IdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPp[5FKSzVyPUGuN|A4OjVizszN MYXTRW5ITVJ?
SW1463 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwM{G4O|Ih|ryP Mm\4V2FPT0WU
COLO-668 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTIfpVyUUN3ME2xMlM{ODV4IN88US=> NEi0eYdUSU6JRWK=
PANC-08-13 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7OTXh2UUN3ME2xMlM{QDB|IN88US=> M4XnUXNCVkeHUh?=
BB49-HNC M2TEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwM{SwNUDPxE1? NX7vXmZYW0GQR1XS
M059J NUjmWYFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELTZ4pKSzVyPUGuN|U5OzJizszN MVvTRW5ITVJ?
NCCIT NIfwbZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxTWM2OD1zLkO3PVg5KM7:TR?= NWPJXHQ5W0GQR1XS
LN-405 NEfXdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvTWM2OD1zLkO5NlY1KM7:TR?= Mo\FV2FPT0WU
UMC-11 NYjqeHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\5TmlEPTB;MT6zPVk6PiEQvF2= NIrUV4xUSU6JRWK=
NB5 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDsSHJTUUN3ME2xMlQyOjJ5IN88US=> MYjTRW5ITVJ?
TE-441-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DqemlEPTB;MT60NlgyPyEQvF2= Mmj4V2FPT0WU
ME-180 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7aeGhKSzVyPUGuOFQ{QTJizszN MoDDV2FPT0WU
HCC70 NIfYeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTpTWM2OD1zLkS2NFk3KM7:TR?= MlLrV2FPT0WU
no-10 NFPncZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwNE[xPFEh|ryP NGrRXmJUSU6JRWK=
JEG-3 NYnZNoFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInGUYNKSzVyPUGuOVAyOzJizszN MX\TRW5ITVJ?
no-11 NVTKTVNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj6W41KSzVyPUGuOVA5QDJizszN MUDTRW5ITVJ?
CHP-126 NWjyXoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W5emlEPTB;MT61OlY6OSEQvF2= NE[1flBUSU6JRWK=
EGI-1 NHPFWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjJXIdSUUN3ME2xMlU5ODJ3IN88US=> NIn2XlBUSU6JRWK=
D-392MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYTWM2OD1zLkW5OlMh|ryP NXvafVRmW0GQR1XS
RT4 NELjV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjPc41FUUN3ME2xMlU6PjN5IN88US=> MWTTRW5ITVJ?
A204 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HCPGlEPTB;MT61PVgxOSEQvF2= M{LlUnNCVkeHUh?=
NCI-H1304 NH;yfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwNkO1PVEh|ryP M37JfnNCVkeHUh?=
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jod2lEPTB;MT62OFI1OSEQvF2= NFXS[WhUSU6JRWK=
OE19 NGPnbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULi[WtjUUN3ME2xMlY2PTF6IN88US=> NH;wcI1USU6JRWK=
EKVX Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHDPWZpUUN3ME2xMlY2PjF6IN88US=> M4n1bXNCVkeHUh?=
KLE NVPVcopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITzU2JKSzVyPUGuOlU4OTRizszN MUHTRW5ITVJ?
K-562 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLje5FWUUN3ME2xMlY4ODN5IN88US=> MYHTRW5ITVJ?
MDA-MB-175-VII Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLaeoI{UUN3ME2xMlY5QTl5IN88US=> NHLWUGJUSU6JRWK=
NCI-H716 NWTyVmVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S5SGlEPTB;MT62PVMxPCEQvF2= Mor0V2FPT0WU
Caov-3 M2nQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLjTWM2OD1zLk[5OFE{KM7:TR?= MkjVV2FPT0WU
HCC1187 NIjQenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rEbmlEPTB;MT63NFU1PSEQvF2= NXy3cYNbW0GQR1XS
CAKI-1 M2\YWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XXVGlEPTB;MT63NlI6OiEQvF2= NIraS21USU6JRWK=
MOLT-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwN{OzNFch|ryP Ml;rV2FPT0WU
PC-3 NWf0VYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwN{WwPEDPxE1? NELvN5ZUSU6JRWK=
DV-90 NUXXZox6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLETIpDUUN3ME2xMlc2PTh3IN88US=> NFHWenpUSU6JRWK=
RXF393 M4H2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTBd3pZUUN3ME2xMlc4Ojl2IN88US=> NVLIRVF7W0GQR1XS
SK-NEP-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPGWpJKSzVyPUGuPFI{OzlizszN NE\ke|lUSU6JRWK=
HCC1419 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHETWM2OD1zLkiyOlkzKM7:TR?= NUL1VZRjW0GQR1XS
BV-173 NFPDWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXGTWM2OD1zLkiyPVk2KM7:TR?= MULTRW5ITVJ?
MKN7 MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;ZUGFKSzVyPUGuPFkzOiEQvF2= MoDvV2FPT0WU
LAN-6 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTFwOEm1OVMh|ryP M{nQSHNCVkeHUh?=
Mo-T NVzkWpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonLTWM2OD1zLkmwNFM6KM7:TR?= MU\TRW5ITVJ?
HCC1395 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\ndXJKSzVyPUGuPVI5PjNizszN NIDRTIVUSU6JRWK=
HC-1 NIjYSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\yR3R5UUN3ME2xMlk{PDdizszN NYHXTZc6W0GQR1XS
HPAF-II MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXkWZdKSzVyPUGuPVQ1OThizszN NV\XbWM{W0GQR1XS
CPC-N M4nHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnnSlV[UUN3ME2xMlk5ODB{IN88US=> M3\INnNCVkeHUh?=
MKN45 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfkclU{UUN3ME2xMlk6OTF7IN88US=> NV3sdpdDW0GQR1XS
NCI-H1693 M3vO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJwMEC0N|Mh|ryP MUTTRW5ITVJ?
SHP-77 NHfZUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFm4d|lKSzVyPUKuNFA2OzNizszN M4X2THNCVkeHUh?=
NCI-H1522 Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrMTWM2OD1{LkCxO|I1KM7:TR?= NH;GNodUSU6JRWK=
SW1573 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHr[FF{UUN3ME2yMlAzOiEQvF2= MnHKV2FPT0WU
DBTRG-05MG MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;xTWM2OD1{LkC2NFg4KM7:TR?= MYnTRW5ITVJ?
SCC-4 NXrEbYhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3KTWM2OD1{LkG0N|Eh|ryP NXzoZ2JIW0GQR1XS
DMS-153 NXXjPW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJwMU[2Olgh|ryP NEPBbpZUSU6JRWK=
MDA-MB-415 MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwMUe1NkDPxE1? MnfaV2FPT0WU
NCI-H2126 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHqTWxKSzVyPUKuNlI5QDhizszN MWnTRW5ITVJ?
MDA-MB-453 M1;QdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPkTWM2OD1{LkKzN|Ih|ryP M4LaOnNCVkeHUh?=
U-87-MG NHHrOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnG[|NDUUN3ME2yMlI5PTl{IN88US=> MnjwV2FPT0WU
LNCaP-Clone-FGC MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJwM{CxNFIh|ryP M4jjSXNCVkeHUh?=
NCI-H1581 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD1{LkOyNVA2KM7:TR?= MV;TRW5ITVJ?
BC-3 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwM{[1NFkh|ryP M1rXN3NCVkeHUh?=
HCC38 M1K4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrhdHVNUUN3ME2yMlM5PDR5IN88US=> NU\sXGlWW0GQR1XS
HCC2218 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwNEC4NFkh|ryP NXnhZWlMW0GQR1XS
RO82-W-1 NYTJU3Z5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJwNEGyOUDPxE1? NYDwXHo2W0GQR1XS
C2BBe1 M{noXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwNEG1O|gh|ryP NUXDSXZ3W0GQR1XS
LAMA-84 M4TveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUewVJlkUUN3ME2yMlU4OzZ6IN88US=> NXzEZmtzW0GQR1XS
GMS-10 NHfNVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj6V|RKSzVyPUKuOVc3OTFizszN MlzVV2FPT0WU
GCT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPkUHNKSzVyPUKuOVg3QTRizszN NYLjRYI1W0GQR1XS
SK-CO-1 M1fFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7zOpp5UUN3ME2yMlYyPjZizszN MXrTRW5ITVJ?
NCI-H526 NWnncphZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\tTWM2OD1{Lk[zOFUh|ryP NH7zN|hUSU6JRWK=
SW1088 M{\sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\zOIxuUUN3ME2yMlc4QDN7IN88US=> MVjTRW5ITVJ?
HT55 NWHDT3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mxNmlEPTB;Mj63PFY6PSEQvF2= NGrDWJNUSU6JRWK=
NB10 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXz1eWFlUUN3ME2yMlgyPzR6IN88US=> NFPqSZJUSU6JRWK=
UACC-893 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HnRWlEPTB;Mj64OVc1QSEQvF2= NGPrXmdUSU6JRWK=
NCI-H1618 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rHVGlEPTB;Mj64PFE2OyEQvF2= NH;Lc5JUSU6JRWK=
NCI-H1092 NIjidXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHuTWM2OD1|LkC3PFEzKM7:TR?= NH6yNZFUSU6JRWK=
SBC-1 M2rHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:wR4FkUUN3ME2zMlA5PTV|IN88US=> Mn3YV2FPT0WU
NCI-H1623 NHHacGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfnW45FUUN3ME2zMlA6OzRizszN M4XtcHNCVkeHUh?=
SiHa NXTuN4VCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrzTWM2OD1|LkGxPVc4KM7:TR?= NGXjWHdUSU6JRWK=
D-263MG NV;6NpkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq4TWM2OD1|LkG0O|g5KM7:TR?= M4DDXXNCVkeHUh?=
NCI-H1573 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTNwMUm2OFEh|ryP NF2yO5dUSU6JRWK=
NCI-H82 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjhTIc2UUN3ME2zMlM1PDN7IN88US=> NUXzPFFZW0GQR1XS
NCI-H2196 NUj4OFRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;hTZZKSzVyPUOuN|UxODhizszN MXrTRW5ITVJ?
MFM-223 M4ribmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNwM{ezOVEh|ryP MWDTRW5ITVJ?
COLO-678 M1fPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S1UGlEPTB;Mz6zPFE5PiEQvF2= MonHV2FPT0WU
EW-3 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNwNEC5OUDPxE1? MV\TRW5ITVJ?
MHH-NB-11 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDjbo1KSzVyPUOuOFQxPjlizszN NVKweZJwW0GQR1XS
EM-2 NHnremVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwNkO5PEDPxE1? NIe2OlBUSU6JRWK=
FTC-133 M{LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\rTWM2OD1|Lk[1OFU5KM7:TR?= NHj1WWxUSU6JRWK=
NCI-H209 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13qSGlEPTB;Mz62O|Y2OyEQvF2= M{jkSXNCVkeHUh?=
TGBC24TKB MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f0PWlEPTB;Mz62PFM2PSEQvF2= MX;TRW5ITVJ?
LC-1F NYHBcJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XKemlEPTB;Mz63NVc3PCEQvF2= MorEV2FPT0WU
C-4-II M{L3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDFdJNKSzVyPUOuO|U3PDNizszN NGrMcIxUSU6JRWK=
NCI-H1650 M{S4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPjd|h[UUN3ME2zMlc5PDV3IN88US=> M3PKcHNCVkeHUh?=
JVM-2 M1LLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTHTWM2OD1|LkmzOlM6KM7:TR?= MUjTRW5ITVJ?
CaR-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7xbnBKSzVyPUOuPVc3OTdizszN M123b3NCVkeHUh?=
MDA-MB-134-VI NWTYdIJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD12LkCyPVUzKM7:TR?= NXjmSXdUW0GQR1XS
NCI-H719 NUeyXpI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TSSGlEPTB;ND6xOVM5QCEQvF2= NXTrcXFuW0GQR1XS
GOTO M4DnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zJUWlEPTB;ND6yPVcxPSEQvF2= NHLTVlJUSU6JRWK=
NCI-N87 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\KcWRKSzVyPUSuN|g5OjFizszN MnriV2FPT0WU
NB6 NHrFVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRwNEK1NFkh|ryP MVjTRW5ITVJ?
DSH1 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\5O3JKSzVyPUSuOFcyOTZizszN NH;4XZFUSU6JRWK=
BT-20 NFnu[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwNEmwNFIh|ryP MnjiV2FPT0WU
NCI-H1882 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW1[npCUUN3ME20MlUxPTdizszN NYjTVo5GW0GQR1XS
WM-115 NHj6PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTiTWM2OD12LkWwPFgyKM7:TR?= Mn;oV2FPT0WU
SKG-IIIa MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jmWmlEPTB;ND62O|c4KM7:TR?= NHTUbmhUSU6JRWK=
NCI-H69 NVnGVoNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTZV4NmUUN3ME20MlcxOjd3IN88US=> NH;oZ21USU6JRWK=
MSTO-211H NIHBd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr0PZhKSzVyPUSuPFM2PjVizszN M2riOHNCVkeHUh?=
Mewo NV7pRYNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G1cWlEPTB;ND65OlMyOyEQvF2= NYXq[WlEW0GQR1XS
GI-ME-N MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTVwMEC1NFkh|ryP MX;TRW5ITVJ?
T98G NUDLcVJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TQfGlEPTB;NT6wOlUxQCEQvF2= MVzTRW5ITVJ?
ECC4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HMdGlEPTB;NT6wPVM4OiEQvF2= NWi0SJlJW0GQR1XS
EW-11 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PmWWlEPTB;NT6xPFA6QSEQvF2= MX;TRW5ITVJ?
COLO-800 NEHaW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwMUmzOFkh|ryP NVnYS3doW0GQR1XS
NCI-H1755 NUC1dZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtSmlEPTB;NT6yN|AzPyEQvF2= MVLTRW5ITVJ?
KMS-12-PE NH\XbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4bYFKSzVyPUWuN|UxQDVizszN M1LjdXNCVkeHUh?=
HCC1954 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfyc2ZKSzVyPUWuPFU6PzFizszN NHT6VlVUSU6JRWK=
NCI-H187 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwOUK5PFkh|ryP MVnTRW5ITVJ?
LU-165 NInrblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwOUmwNFIh|ryP NW\qWG5VW0GQR1XS
YAPC NIrWfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGxNolMUUN3ME21Mlk6ODZ6IN88US=> M2XieXNCVkeHUh?=
LU-139 NIfZT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTZwMEizOlgh|ryP M3rnOHNCVkeHUh?=
D-502MG NWnYU2I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTZwM{KwOFch|ryP MkX3V2FPT0WU
IST-SL1 MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPoTWM2OD14LkWzPVQ5KM7:TR?= NXXSPGdUW0GQR1XS
DG-75 NXPqeJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTZwOEi3PFYh|ryP NHHhSWhUSU6JRWK=
NCI-H1155 M1G0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nuSmlEPTB;Nj65OVU5OSEQvF2= M1K0PXNCVkeHUh?=
EFE-184 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrNUZhKSzVyPUeuN|E3QTVizszN NVfQZ2NEW0GQR1XS
AsPC-1 M4\ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPwTWM2OD15LkS4PFA4KM7:TR?= M2DWWnNCVkeHUh?=
SW948 NV3VcY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTDU5lrUUN3ME23MlU5Ozl3IN88US=> MUDTRW5ITVJ?
NCI-H524 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmKxTWM2OD17LkW4OlI5KM7:TR?= NVrjUZhVW0GQR1XS
KOSC-2 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTPTWM2OD17Lk[yPFM1KM7:TR?= MU\TRW5ITVJ?
T-24 M2LwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwOUS0NVUh|ryP MVrTRW5ITVJ?
NCI-H748 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q4[WlEPTB;MUCuOlM6PyEQvF2= NYS5bFJYW0GQR1XS
NCI-H23 NF7rVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPRWxKSzVyPUGwMlY1PDJizszN NX7G[5YxW0GQR1XS
UACC-812 NX;mUHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorSTWM2OD1zMT63NVch|ryP M4q3V3NCVkeHUh?=
SCLC-21H NVLMfm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF{LkG1OVEh|ryP NHGxSHpUSU6JRWK=
NCI-SNU-16 NInpWWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvKTYZDUUN3ME2xN{4yOjV6IN88US=> NXrzWI5kW0GQR1XS
HD-MY-Z M{LNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF2Lk[zOlMh|ryP M4PhdXNCVkeHUh?=
SK-N-FI NV\PdpJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2Lki5NVIh|ryP MUjTRW5ITVJ?
LB647-SCLC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\3boFKSzVyPUG1MlcyQTVizszN NFTQcJFUSU6JRWK=
NCI-H345 NYLKcGdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF5LkO0N{DPxE1? NF;YPYRUSU6JRWK=
NCI-H1563 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uxRmlEPTB;MUiuO|YxOSEQvF2= NI\FSFRUSU6JRWK=
RL NVvWc5U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jpWWlEPTB;MkGuNlY2PiEQvF2= M3XEWHNCVkeHUh?=
KY821 NVHKXnU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;VNmlEPTB;MkKuNFU2OyEQvF2= NXPKd3ZWW0GQR1XS
JVM-3 NXvHbmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7GcHFKSzVyPUK1MlA1OTNizszN NXPZdJk{W0GQR1XS
NCI-H1793 M3K3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{C1NmlEPTB;MkiuOVQ6QSEQvF2= MlLWV2FPT0WU
LU-134-A NH\iVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUfJVCUUN3ME2zNE4zODN5IN88US=> M3S5VXNCVkeHUh?=
NCI-H1395 NH;jblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnrdXlKSzVyPUOyMlI1OzFizszN MUjTRW5ITVJ?
NCI-H1993 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPzTWM2OD1|Mj64NlE5KM7:TR?= Mlu3V2FPT0WU
P31-FUJ NFPMbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjmZYFKSzVyPUOzMlQ5QTlizszN MlnLV2FPT0WU
LS-513 M{jONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGyVnJKSzVyPUO1Mlg5PzlizszN NFn0cIZUSU6JRWK=
SK-MEL-1 M{XFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XBV2lEPTB;NECuN|Q6QSEQvF2= NVTTWWRqW0GQR1XS
SW684 NX3K[Yh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny3TWM2OD12Mz65OlYyKM7:TR?= NFjWcZpUSU6JRWK=
COR-L88 Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPaU4FsUUN3ME20OE4xPjZ3IN88US=> MUfTRW5ITVJ?
NCI-H889 NHvYOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTR3LkCwPFch|ryP NWDXXmkxW0GQR1XS
TALL-1 NVzZOVQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR4LkGxPVkh|ryP NHXySWFUSU6JRWK=
KARPAS-299 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPLN5BKSzVyPUS3MlE6QTNizszN NEnVSXZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID